Company: BIAF
Filing Date: 2025-05-02
Form Type: S-1
Source: 0001641172-25-008170
Chunk: 3

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-02
Form: S-1
Chunk 3
---
 prior to the expiration of the April 2025 Warrants and (ii) a decrease of the exercise price of the April 2025 Warrants, if in a subsequent offering of our securities the price paid for Common Stock, the exercise price of any options or warrants or the conversion price of any convertible securities issued in such subsequent offering is less than the exercise price immediately prior to such subsequent offering , to an exercise price that is equal to the lowest of the price paid for Common Stock, the exercise price of any options or warrants or the conversion price of any convertible securities issued in such subsequent offering (subject to a floor of $0.10 per share) and an increase in the number of shares of our Common Stock underlying the April 2025 Warrants upon such exercise price reset so that the reset exercise price multiplied by the increased number of shares equals the aggregate proceeds that would have resulted from the full exercise of the April 2025 Warrants immediately prior to the reset. If a reverse stock split is effected and then a subsequent offering occurs for which the exercise price of the April 2025 Warrants is reset to the floor price of $0.10 per share, then based on an assumed initial exercise price of $0.5489 per share (equal to 110% of the assumed combined offering price per Share and accompanying April 2025 Warrant), the number of shares of Common Stock underlying each April 2025 Warrant would be increased to 7.1 shares and a total of 75,074,993 shares of Common Stock would be issuable upon exercise of all of the April 2025 Warrants.

We are also offering to those purchasers, if any, whose purchase of shares of Common Stock in this offering would result in such purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding Common Stock following the consummation of this offering, the opportunity to purchase, in lieu of the shares of our Common Stock that would otherwise result in the purchaser’s beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%), pre-funded warrants (the “Pre-Funded Warrants”) each to purchase one share of Common Stock at an exercise price of $0.007 per share. Each Pre-Funded Warrant is being issued together with one April 2025 Warrant to purchase one and one-half share of Common Stock. The